GSA Capital Partners LLP Has $279,000 Stock Position in Nektar Therapeutics (NASDAQ:NKTR)

GSA Capital Partners LLP decreased its position in Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 77.0% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 214,245 shares of the biopharmaceutical company's stock after selling 716,698 shares during the period. GSA Capital Partners LLP owned about 0.12% of Nektar Therapeutics worth $279,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Bank of New York Mellon Corp boosted its position in Nektar Therapeutics by 2,822.5% during the second quarter. Bank of New York Mellon Corp now owns 551,535 shares of the biopharmaceutical company's stock valued at $684,000 after purchasing an additional 532,663 shares during the last quarter. Nantahala Capital Management LLC boosted its holdings in shares of Nektar Therapeutics by 66.0% in the 2nd quarter. Nantahala Capital Management LLC now owns 4,110,000 shares of the biopharmaceutical company's stock valued at $5,096,000 after buying an additional 1,634,046 shares during the last quarter. Samlyn Capital LLC bought a new position in shares of Nektar Therapeutics in the second quarter valued at $11,728,000. Millennium Management LLC increased its holdings in Nektar Therapeutics by 56.1% during the second quarter. Millennium Management LLC now owns 4,659,469 shares of the biopharmaceutical company's stock worth $5,778,000 after buying an additional 1,674,924 shares during the last quarter. Finally, Armistice Capital LLC acquired a new position in Nektar Therapeutics during the second quarter worth $1,037,000. Institutional investors and hedge funds own 75.88% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. BTIG Research reiterated a "buy" rating and issued a $4.00 price target on shares of Nektar Therapeutics in a research note on Monday, September 30th. Piper Sandler initiated coverage on shares of Nektar Therapeutics in a research note on Monday, November 4th. They issued an "overweight" rating and a $7.00 target price for the company. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, Nektar Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $3.50.

Nektar Therapeutics Price Performance

NKTR traded up $0.04 during trading on Friday, hitting $1.05. The stock had a trading volume of 4,632,234 shares, compared to its average volume of 1,852,490. The company has a 50 day moving average price of $1.27 and a 200-day moving average price of $1.31. Nektar Therapeutics has a one year low of $0.42 and a one year high of $1.93. The firm has a market cap of $193.68 million, a price-to-earnings ratio of -1.25 and a beta of 0.61.

Nektar Therapeutics Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.